LTZ Therapeutics, Inc.
LTZ Therapeutics is a global biotech company focused on immunotherapy, pioneering a novel Myeloid Engager Platform guided by reverse translational science and emerging disease biology. Their mission is to develop innovative therapies in oncology and autoimmune diseases, leveraging the power of myeloid cell subsets, particularly macrophages, to improve patient outcomes and aim to eliminate cancer.
Industries
Nr. of Employees
small (1-50)
LTZ Therapeutics, Inc.
San Francisco, California, United States, North America
Products
LTZ-301 (CD79b)
A myeloid-engager bispecific therapeutic candidate targeting CD79b intended to treat relapsed or refractory non-Hodgkin lymphoma; subject of an FDA IND clearance to initiate clinical study.
LTZ-232 (EpCAM)
A myeloid-engager candidate directed against EpCAM for solid tumors and malignant ascites (listed in the company's development pipeline).
LTZ-233
A myeloid-engager candidate listed for solid tumor indications in the company's pipeline (development stage not detailed on public pipeline page).
LTZ-301 (CD79b)
A myeloid-engager bispecific therapeutic candidate targeting CD79b intended to treat relapsed or refractory non-Hodgkin lymphoma; subject of an FDA IND clearance to initiate clinical study.
LTZ-232 (EpCAM)
A myeloid-engager candidate directed against EpCAM for solid tumors and malignant ascites (listed in the company's development pipeline).
LTZ-233
A myeloid-engager candidate listed for solid tumor indications in the company's pipeline (development stage not detailed on public pipeline page).
Services
Preclinical development and IND-enabling studies
In-house discovery-to-IND workflow including target validation, mechanism-of-action studies, safety-focused pharmacology, and preparation of IND packages.
Antibody engineering and developability optimization
Engineering of antibody constructs (Fc and variable regions) to enhance effector function, stability, manufacturability, and reduce heterogeneity.
Preclinical development and IND-enabling studies
In-house discovery-to-IND workflow including target validation, mechanism-of-action studies, safety-focused pharmacology, and preparation of IND packages.
Antibody engineering and developability optimization
Engineering of antibody constructs (Fc and variable regions) to enhance effector function, stability, manufacturability, and reduce heterogeneity.
Expertise Areas
- Myeloid-engager immunotherapy development
- Bispecific antibody design and engineering
- Antibody Fc engineering and CMC optimization
- Preclinical and IND-enabling development
Key Technologies
- Bispecific antibody platform
- Fc engineering to modulate Fcγ receptor interactions
- Phagocytosis activation via innate myeloid receptors
- Antigen cross-presentation